The U.S. Food and Drug Administration (FDA) has granted approval of Immunocore’s KIMMTRAK (tebentafusp-tebn) to treat adults who are HLA-A*02:01-positive for unresectable or metastatic uveal melanoma (mUM). Uveal melanoma is a rare and aggressive cancer of the eye, in which tumors form from melanocytes in the uvea region. KIMMTRAK (tebentafusp-tebn) is a novel bispecific protein, including a soluble T cell receptor fused to an anti-CD3 immune-effector function to target the lineage antigen gp100. There are no cures for unresectable or metastatic uveal melanoma (mUM), but some of the common treatment options include radiation therapy, tumor removal surgery, or a total enucleation. Immunocore is a commercial-stage biotech company that develops TCR bispecific immunotherapies to treat autoimmune disorders, infectious diseases, and cancers.

Read more here.